Neuralink, Elon Musk's neurotechnology company, has achieved a significant milestone by receiving Breakthrough Device ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment ...

The device helps identify NSCLC subjects who are likely to benefit from Daiichi Sankyo and AstraZeneca’s Datroway’s treatment ...

The company said that its applications can be extended to individuals affected by ALS, stroke, spinal cord injury, cerebral ...

The biotech company Roche is receiving support towards its efforts to advance cancer diagnosis and digital pathology ...

The device is designed to lower blood pressure while simultaneously modulating the autonomic nervous system by delivering ...

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA ...

Neuralink said on social media that it received FDA breakthrough device designation for treating individuals with severe ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

Elon Musk announced plans to make Neuralink's brain-computer interface technology "widely available" following the company's ...

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk ...